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Abstract: Human respiratory syncytial virus (HRSV) is an important cause of severe respiratory tract
disease in immunocompromised patients. Animal models are indispensable for evaluating novel
intervention strategies in this complex patient population. To complement existing models in rodents
and non-human primates, we have evaluated the potential benefits of an HRSV infection model
in ferrets (Mustela putorius furo). Nine- to 12-month-old HRSV-seronegative immunocompetent
or immunocompromised ferrets were infected with a low-passage wild-type strain of HRSV
subgroup A (105 TCID50) administered by intra-tracheal or intra-nasal inoculation. Immune
suppression was achieved by bi-daily oral administration of tacrolimus, mycophenolate mofetil,
and prednisolone. Throat and nose swabs were collected daily and animals were euthanized four,
seven, or 21 days post-infection (DPI). Virus loads were determined by quantitative virus culture
and qPCR. We observed efficient HRSV replication in both the upper and lower respiratory tract.
In immunocompromised ferrets, virus loads reached higher levels and showed delayed clearance as
compared to those in immunocompetent animals. Histopathological evaluation of animals euthanized
4 DPI demonstrated that the virus replicated in the respiratory epithelial cells of the trachea, bronchi,
and bronchioles. These animal models can contribute to an assessment of the efficacy and safety of
novel HRSV intervention strategies.
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1. Introduction
Human respiratory syncytial virus (HRSV) is a member of the family Paramyxoviridae, genus
Pneumovirus. Although most HRSV infections remain restricted to the upper respiratory tract (URT)
and are associated with relatively mild clinical signs, approximately 0.5%–2% of primary infections in
infants below six months of age result in severe bronchiolitis or pneumonia requiring hospitalization [1].
Young infants with a history of premature birth and those with congenital heart or lung disease
have an increased risk of developing severe disease upon primary HRSV infection [2]. Another
high-risk group of severe HRSV disease is found at the other extreme of age—the frail elderly—with
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progressively waning immunity, in which HRSV is recognized as an important cause of morbidity
and mortality [3]. A third high-risk group of severe HRSV disease is formed of individuals who are
immunocompromised, either iatrogenically upon e.g., cell or organ transplantation or cancer treatment,
or through inherited or acquired immunodeficiency [4–6].
Since the introduction of sensitive and reliable molecular biological diagnostic techniques,
a plethora of respiratory viruses has been detected in transplant recipients with clinical symptoms
of respiratory tract disease [7]. Immunosuppressive medication given to prevent transplant rejection
or graft-versus-host disease causes increased susceptibility to infection, and may lead to prolonged
virus shedding [8–10]. Severity of disease and mortality risk are directly associated with the level
and duration of immunodeficiency [11,12]. Lower respiratory tract (LRT) infections with HRSV
have especially been associated with high morbidity and mortality in allogenic hematopoietic cell
transplant recipients [5,13]. In lung transplant recipients, HRSV infections have been associated with
induction of bronchiolitis obliterans syndrome (BOS) [14]. Therapeutic options are currently restricted
to administration of ribavirin and/or intravenous immunoglobulin (IVIG) [15,16], although several
antiviral compounds are currently in clinical development [2,17].
The population of immunocompromised patients is highly heterogeneous, both in terms of
the origin and level of immune suppression and the presence of co-morbidities, which renders
studies of the safety and efficacy of novel therapeutics difficult to perform. Preclinical studies in
animal models could be instrumental, but all animal models of HRSV infection have limitations [18].
Several animal models have been developed with specific benefits such as high susceptibility (cotton
rats, calves, lambs), availability of immunological reagents and knockout strains (mice), and close
relationship to humans (non-human primates). However, none of these models fully captures all of
these advantages. The human challenge model offers an alternative approach [19–21], but for obvious
reasons these studies do not allow investigation of severe LRT disease and cannot be performed
in individuals belonging to risk groups. Therefore, evaluation of therapeutic safety and efficacy of
antiviral compounds in immunocompromised patients largely depends on phase III clinical studies,
which are expensive and hard to conduct in this heterogeneous patient group.
We recently developed an animal model for influenza virus infection of immunocompromised
patients, by demonstrating that ferrets can be immunocompromised by oral administration of
a combination of immunosuppressive compounds used in transplantation patients, including
tacrolimus, mycophenolate mofetil (MMF), and prednisolone [8]. Indeed, observations in the
immunocompromised ferrets were comparable to those in humans with prolonged influenza virus
shedding and emergence of antiviral resistance. The ease of handling the animals allowed for daily
collection or respiratory tract swabs, which enabled detailed studies of the kinetics of virus replication.
However, whereas ferrets are among the best animal species for modeling human influenza, previous
reports of HRSV infections in ferrets have yielded disappointing results. In particular, Prince and
Porter infected ferrets of different ages with the Long strain of HRSV, and showed that the virus
replicated well in the URT, but poorly in the LRT [22]. Moreover, replication in the LRT proved to be
age-dependent and restricted to infant ferrets.
We have infected immunocompetent and immunocompromised ferrets with a low-passage
wild-type strain of HRSV subgroup A. We demonstrate that the wild-type virus efficiently replicates in
both the URT and LRT of nine- to 12-month-old ferrets. In addition, we demonstrate prolonged virus
shedding in immunocompromised animals, as detected both by qPCR and virus isolation.
2. Materials and Methods
2.1. Ethics Statement and Animal Care and Use
The study protocol and compliance with 3R policies was approved by the Independent Animal
Experimentation Ethics Committee in Driebergen, The Netherlands (permit number BXT0014,
approval date 8 September 2014). Animals were housed and experiments were conducted in strict
compliance with European guidelines (EU directive on animal testing 86/609/EEC) and Dutch
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legislation (Experiments on Animals Act, 1997). The manuscript was prepared in accordance with the
ARRIVE guidelines.
Ferrets (Mustela putorius furo) were nine- to 12-month-old purpose-bred females and were
seronegative for Aleutian disease virus, circulating influenza virus (sub) types A/H1N1, A/H3N2,
and B virus, and RSV subgroup A and B. All ferrets carried a sub-cutaneous chip with their individual
animal number. The ferrets, in the weight range of 570–940 g, were maintained in groups of three in
cages with a floor area of 12,240 cm2 with sawdust bedding (Lignocel®, Rettenmaier & Sohne GmbH,
Rosenberg, Germany) in accordance with the Code of Practice for the Housing and Care of Animals
Bred, Supplied or Used for Scientific Purposes (December 2014).
Animals were provided with cage enrichment (toys and hiding places) and were housed under
a 12 h photoperiod regime. Five-week-old female specified pathogen-free cotton rats (Sigmodon hispidus)
were obtained from Harlan Laboratories, Horst, The Netherlands. Cotton rats were housed individually
in filter-top cages with wood fiber bedding, and were provided with paper towels as cage enrichment.
All animals were fed commercial food pellets and offered water ad libitum. Animal welfare criteria
were verified on a daily basis. Handling of ferrets was performed as follows:
‚ Twice-daily oral dosing with immunosuppressive medication and daily collection of throat- and
nose swabs without sedation;
‚ Inoculation and preparation for anesthesia: sedation with a mixture of ketamine and
medetomidine (IM doses of 0.2 and 0.01 mL/kg body weight (bw), respectively). After inoculation
the effect of the medetomidine was antagonized with atipamezole (0.005 mL/kg bw) upon
completion of the procedure;
‚ Blood sampling: sedation with ketamine (intra-muscular [IM] dose of 0.2 mL/kg bw);
Handling of cotton rats was performed under light 4% isoflurane inhalation anesthesia.
2.2. Cells and Virus
Human respiratory epithelium carcinoma cells (HEp-2 cells, ATCC® CCL-23™) were cultured
in Dulbecco’s Modified Eagle Medium (DMEM; Lonza, Breda, The Netherlands) supplemented
with L-glutamine, penicillin, streptomycin and 10% FBS (Greiner Bio-One, Alphen aan Den Rijn,
The Netherlands), further referred to as Hep-2 medium.
A wild-type HRSV subgroup A strain was isolated in HEp-2 cells from a nasal lavage of an infant
hospitalized at Erasmus MC, Rotterdam, The Netherlands, in 2011. The virus was passaged exclusively
in HEp-2 cells. The challenge stock used in the animal experiments was passage 3, and was prepared
as follows: monolayers of HEp-2 cells were infected at low multiplicity of infection (MOI, ď0.01)
in serum-free HEp-2 medium for 2 h at 37 ˝C, after which Hep-2 medium containing 10% FBS was
added. After 24 h the serum content was reduced to 2% FBS by removing the medium and adding
a serum-free medium. Cytopathic effect (CPE) was followed and cell-free virus was harvested at
approximately 50%–75% CPE. Supernatant was clarified by centrifugation for 15 min at 1200 g, and
subsequently aliquots were snap-frozen using a mixture of 96% ethanol and dry ice and stored at
´80 ˝C. No stabilizers were added to the medium. Virus titers were determined by end-point titration
on monolayers of HEp-2 cells and CPE screening six days after infection, and viral titers were calculated
using the method of Spearman and Karber. The challenge stock tested negative for a large panel of
respiratory human viruses and mycoplasmas by RT-PCR.
2.3. Immunosuppressive, Antibiotic, and Antiviral Drugs
The following immunosuppressive drugs were used to suppress the immune system of
ferrets: Mycophenolate mofetil (MMF) (CellCept®, Roche, Woerden, The Netherlands) powder for
infusion, tacrolimus concentrate (5 mg/mL) for infusion (Prograft®, Astellas Pharma BV, Leiderdorp,
The Netherlands), and prednisolone sodium phosphate (5 mg/mL) oral solution (Hospital Pharmacy,
UMCN St Radboud, Nijmegen, The Netherlands). Infusion grade was chosen for MMF and tacrolimus
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for practical reasons: this provided a liquid formulation of appropriate concentration. To prevent
opportunistic bacterial infections due to immune suppression, an antibiotic prophylaxis of amoxicillin
supplemented with clavulanic acid (250 mg and 62.5 mg per 5 mL, respectively) oral suspension
(Pharmachemie BV, Haarlem, The Netherlands) was used based on dose optimization as described
earlier [8]. The HRSV F protein-specific monoclonal antibody Palivizumab (Synagis; AbbVie Ltd.,
Maidenhead, UK) was reconstituted according to the manufacturer’s instructions.
2.4. Human Respiratory Syncytial Virus (HRSV) Infections of Cotton Rats
Cotton rats were inoculated intra-nasally (IN) with 105 TCID50 HRSV-A in an inoculum volume of
100 µL, known to result in virus delivery both in the URT and the LRT [23]. Throat swabs were obtained
daily, under light 4% isoflurane anesthesia. Necropsies were performed according to a standardized
protocol. Nose washes were obtained, followed by lung, nasal turbinate, trachea, and bronchus.
Six animals were infected in the framework of this study, and euthanized at 4 (n = 3) or 21 (n = 3) days
post-infection (DPI) by exsanguination under anesthesia.
2.5. HRSV Infections of Ferrets: Study Design
Twenty-seven ferrets were randomly assigned to treatment groups of three animals each, divided
over two experiments (Table 1). After a one-week acclimatization period, 15 animals were started on the
immunosuppression protocol, including daily oral prophylactic antibiotics (10 mg/kg bw amoxicillin
and 2.5 mg/kg bw clavulanic acid; starting four days before HRSV infection) and twice-daily oral
immunosuppressants (20 mg/kg bw MMF, 0.5 mg/kg bw tacrolimus and 8 mg/kg bw prednisolone;
starting three days before HRSV infection), as described in Section 2.3 and reference [8]. One group of
immunocompromised animals also received intra-muscular Palivizumab (15 mg/kg bw), on days ´2,
0, and 2 relative to HRSV infection. On day 0, all animals were infected with 105 TCID50 low-passage
wild-type HRSV subgroup A by intra-tracheal (IT) or intra-nasal (IN) inoculation with a volume of 3
or 0.3 mL, respectively. Throat (Copan; rayon tipped) and nose (Copan; polyester tipped) swabs were
collected daily in a 3-mL virus transport medium [24], and blood samples were collected ´3, ´2, 0,
2, 4, 6, 14, and 21 DPI. Animals were euthanized by exsanguination at 4, 7, or 21 DPI. All personnel
involved in the collection of study data on a day-to-day basis and all personnel performing the
laboratory analysis in which interpretation of the data is required were not aware of the so-called
Random Treatment Allocation Key at any time prior to completion of the study. All samples were
labeled with a unique sample number.
Table 1. Study design.
Exp # Group # # Ferrets Route Dose IC PZ Necropsy
1 1 3 IT 105 TCID50 No No 4 DPI
1 2 3 IT 105 TCID50 No No 21 DPI
1 3 3 IT 105 TCID50 Yes No 4 DPI
1 4 3 IT 105 TCID50 Yes No 21 DPI
1 5 3 IT 105 TCID50 Yes Yes 21 DPI
2 6 3 IT 105 TCID50 No No 7 DPI
2 7 3 IN 105 TCID50 No No 21 DPI
2 8 3 IT 105 TCID50 Yes No 7 DPI
2 9 3 IN 105 TCID50 Yes No 21 DPI
Exp # Group # # Cotton rats Route Dose IC PZ Necropsy
1 10 3 IN * 105 TCID50 No No 4 DPI
1 11 3 IN * 105 TCID50 No No 21 DPI
DPI = days post-infection; Exp # = experiment number; IT = intra-tracheal; IN = intra-nasal;
IC = immunocompromised; PZ = Palivizumab; * IN infection of cotton rats with an inoculum volume of
100 µL results in human respiratory syncytial virus (HRSV) delivery to both the upper respiratory tract (URT)
and lower respiratory tract (LRT).
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2.6. Samples and Assays
After collection, nose washes, nose swabs, and throat swabs were processed within four hours
of sample collection. Infectious virus titers and concentrations of viral RNA were measured by
virus isolation and reverse transcription-PCR (RT-PCR), respectively, as previously described [25].
Right lungs and nasal turbinates as well as samples from the trachea and bronchus were weighed
and subsequently homogenized with a FastPrep-24 (MP Biomedicals, Eindhoven, The Netherlands)
in Hank’s balanced salt solution containing 0.5% lactalbumin, 10% glycerol, 200 U/mL penicillin,
200 µg/mL streptomycin, 100 U/mL polymyxin B sulfate, 250 µg/mL gentamycin, and 50 U/mL
nystatin (ICN Pharmaceuticals, Zoetermeer, The Netherlands) and centrifuged briefly before viral
load assessment by virus isolation and quantitative PCR (qPCR). Infectious virus titers in tissue are
expressed as log10 TCID50 per gram tissue, and infectious virus titer in nose washes and swabs are
expressed as log10 TCID50/mL.
Virus neutralizing (VN) antibody levels were determined using classical end-point neutralization
assay, as described previously [26]. Briefly, serial two-fold dilutions of serum samples were incubated
with approximately 100 TCID50 of RSV (Long strain) for 1 h at 37 ˝C, HEp-2 cells were added, and
the cytopathic effect was monitored during the subsequent seven days. Fifty percent VN titers were
calculated from triplicate cultures using the Reed and Muench method.
Formalin-fixed tissue sections were routinely processed, paraffin embedded and
sectioned at 3–4 µm, deparaffinized with xylene and rehydrated using graded alcohols, and
stained with hematoxylin and eosin for histopathological examination by light microscopy.
For immunohistochemistry (IHC) additional serial slides were sectioned simultaneously and
incubated for 1 h with a goat anti-HRSV-peroxidase (PO) (Virostat, Portland, ME, USA) polyclonal
antibody following antigen retrieval using citric acid buffer. Endogenous PO was blocked with 3%
hydrogen peroxide. The bound PO was visualized by incubating slides with 3-amino-9-ethylcarbazole
for 10 min as substrate, resulting in a reddish brown granular staining of the cytoplasm of RSV-infected
epithelial cells, followed by hematoxylin counterstain. Negative controls were performed in the
absence of the antibody.
3. Results
3.1. HRSV Infection of Immunocompetent Ferrets Results in Productive Virus Replication in the Upper and
Lower Respiratory Tract
Previous studies suggested that HRSV replicates poorly in the LRT of ferrets [22]. Since these
studies were performed by IN inoculation with a laboratory-adapted HRSV strain, we set out to assess
whether IT inoculation of adult immunocompetent ferrets with a low-passage wild-type HRSV strain
would result in productive virus replication in the LRT. Cotton rats were infected in parallel with
the same virus as susceptible controls. In these animals IT infection is difficult to perform, but IN
infection using an inoculum size of 100 µL reproducibly results in infection of both URT and LRT [23].
At necropsy 4 DPI, HRSV loads as determined by qPCR or quantitative virus culture from the throat
swabs, trachea, and lungs of ferrets (group #1) and cotton rats (group #10) were of the same order of
magnitude (Figure 1A–C). Virus loads in nasal swabs and nasal turbinates were substantially higher in
cotton rats, which could probably be explained by the differences in routes of inoculation.
An advantage of working with ferrets is the relative ease of handling the animals, which allows
for daily collection of throat and nose swabs. In immunocompetent ferrets infected by IT inoculation
and euthanized 21 DPI (group #2), HRSV was detected primarily in throat swabs (Figure 1C), although
some virus replication was also detected in nose swabs (Figure 1D). In throat swabs HRSV was
detectable by isolation until 7 DPI, with peak values at 5 DPI. Using qPCR the virus was detectable
until 10 DPI, with peak values at 6 DPI. In nose swabs the virus was exclusively detected by qPCR,
and considering the low viral loads this could not be considered as evidence for replication in the URT.
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Figure 1. Experimental infection of immunocompetent ferrets ith a lo -passage wild-type human
respiratory s ncytial virus (HRSV) subgroup A strain results in productive virus replication in both the
upper and lower respiratory t ct. (A) HRSV loads in the tissues of the upper and lower respiratory
tract of mmunocompetent ferrets of group #1, infected by intra-tracheal (IT) inoculation and euth nized
four days post-infection (DPI); (B) HRSV loads in tissues of the upper and l wer res iratory tract of
immunocompetent cotton rats of group #10, infected with the same virus and dose by IN inoculation
in a volume of 100 µL (known to result in both nasal and lung delivery) and euthanized four days
post-infection (DPI); HRSV loads in throat swab (C,E) and nose swab (D,F) s mples collected daily
from immunocompetent ferrets infected with a dose of 105 TCID50 by IT (C,D) or IN (E,F) inoculation
(group numbers #2 and #7, respectively). All data are presented as geometric means ˘ standard error
of the mean of groups of three animals (see Table 1). Green bars and symbols (ferrets) and light blue
bars (cotton rats) represent HRSV-specific qPCR data, expressed in TCID50 equivalents per mL (or per
gram tissue for samples labeled with an asterisk in panels A and B). Purple bars and symbols (ferrets)
and dark blue bars (cotton rats) represent HRSV isolation data, expressed in TCID50 per mL (or per
gram tissue for samples labeled with an asterisk in panels A and B).
A different pattern was detected in im unocompetent ferrets infected by IN inoculation and
euthanized 21 DPI (group #7). In these animals high HRSV loads were detected both by qPCR and
virus isolation (Figure 1E,F). Kinetics of the virus isolation curves w re largely identical to those
detec d in IT-inoculated animals, with approximately equal peak values in thr at nd nasal swabs
detected at 5 DPI. Whereas th qPCR curve i throat swabs was almost identical to t t of IT infected
animals, HRSV loads detected by qPCR in nose swabs reached much higher levels than those in IT
inoculated animals, reaching peak values at 6 DPI while remaining detectable until 15 DPI.
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3.2. HRSV Infection of Immunocompromised Ferrets Results in Higher and Prolonged Virus Replication in the
Upper and Lower Respiratory Tract
Comparison of HRSV loads in trachea and lungs of immunocompetent or immunocompromised
ferrets infected by IT inoculation and euthanized at 4, 7, or 21 DPI showed higher viral loads
in immunocompromised animals, as detected both by quantitative virus isolation and qPCR
(Figure 2A,B).
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Detection  of HRSV  in  throat  and  nose  swabs  of  IT‐inoculated  immunocompromised  ferrets 
euthanized 21 DPI  (group #4) showed higher not only but also prolonged presence of viral  loads 
(Figure 2C,D). In contrast to the immunocompetent animals (Figure 1D), virus replication was clearly 
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Figure 2. Experimental infection of immunocompromised ferrets with a low-passage wild-type HRSV
subgroup A strain results in higher and prolonged virus replication in both the upper and lower
respi ato y tract. HRSV loads in trachea ( ) l s (B) were d tected by qPCR and virus isolation
after nec opsies at 4, 7, or 21 DPI. HRSV loads in throa swab (C,E) or nose swab (D,F) samples collected
daily from immunocompromised fe rets infected by IT (C,D) or IN (E,F) inoculation (group n mbers
#4 and #9, respectively). All data are presented as geometric means ˘ standard error of the mean of
groups of three animals (Table 1). Immunocompetent and immunocompromised ferrets are shown by
circular and triangle-shaped symbols, respectively; qPCR and virus isolation data by green and purple
symbols, respectively. Viral loads are shown in TCID50 equivalents per gram tissue (A,B) or TCID50
per mL (C–F).
Detection of HRSV in throat and nose swabs of IT-inoculated immunocompromised ferrets
euthanized 21 PI (group #4) showed higher not only but also prolonged presence of viral loads
(Figure 2C,D). In contrast to the immunocompetent animals (Figure 1D), virus replication was clearly
detected in the URT of these animals (Figure 2D), and apparently resulted in a biphasic viral load
curve in throat swabs (Figure 2C). These data suggest that virus detected in throat swabs may have
been produced either in the LRT or the URT.
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Immunocompromised ferrets infected by IN inoculation and euthanized 21 DPI (group #9)
showed a similar pattern of increased and prolonged HRSV replication in throat and nose swabs
(Figure 2E,F). Virus loads detected by virus isolation peaked 9 DPI, several days later than those
detected in immunocompetent animals (as shown in Figure 1E,F). In both IT- and IN-inoculated
animals, virus loads remained detectable by qPCR until 21 DPI in both throat and nose swabs in the
majority of animals (2/3 or 3/3 per group).
3.3. HRSV Replicates in Respiratory Epithelial Cells of the Ferret
Tissue samples collected from ferrets of groups #1 and #3 (infected by IT inoculation and
euthanized 4 DPI) and cotton rats of group #10 (infected by IN inoculation and euthanized 4 DPI) were
processed for HRSV antigen detection. In immunocompetent ferrets, HRSV-infected ciliated respiratory
epithelial cells were detected in the trachea and bronchus, but not in the nose or the bronchioles
(Figure 3A–D). In addition, a few neutrophils, few plasmacytes, and few lymphocytes, and sporadic
eosinophils were present in the lamina propria of the nasal mucosa. Sporadic neutrophils were present
in the tracheal epithelial lining and in the bronchiolar and alveolar lumina. In immunocompromised
ferrets the same cells were detected in the trachea and bronchus, but at higher levels than those
observed in immunocompetent animals, and also in the bronchioles but not in the nose (Figure 3E–H).
In addition, sporadic neutrophils were present in the tracheal epithelial lining and in the bronchiolar
lumina. In cotton rats HRSV antigen-positive respiratory epithelial cells were detected in the
nose, bronchi, and bronchioles, but not in the trachea (Figure 3I–L). In addition, a few neutrophils
and mononuclear cells were present in the lamina propria of the nasal mucosa and in the alveolar
lumina. None of the alveolar epithelial cells of ferrets or cotton rats were found positive for HRSV
antigen expression.
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type HRSV by  intra‐tracheal  (ferrets)  intra‐nasal  (cotton rats,  large volume  inoculum)  inoculation. 
Immunoperoxidase, counterstained with hematoxylin. HRSV antigen is visible as red‐brown staining. 
3.4. Prophylactic Treatment of Immunocompromised Ferrets with Palivizumab Results in Temporary 
Inhibition of HRSV Replication 
Palivizumab  (PZ),  or  Synagis®,  is  an  HRSV‐specific  humanized  monoclonal  antibody 
preparation licensed for prophylactic use in infants at high risk of HRSV disease. It is administered 
Figure 3. Representative photomicrographs of HRSV antigen expression within the cytoplasm of
epithelial cells lining various sections of the respiratory tract of immunocompetent ferrets (A–D),
immunocompromised ferrets (E–H), or cotton rats (I–L) euthanized 4 DPI with 105 TCID50 of
wild-type HRSV by intra-tracheal (ferrets) intra-nasal (cotton rats, large volume inoculum) inoculation.
Immunoperoxidase, counterstained with hematoxylin. HRSV antigen is visible as red-brown staining.
3.4. Prophylactic Treatment of Immunocompromised Ferrets with Palivizumab Results in Temporary Inhibition
of HRSV Replication
Palivizumab (PZ), Synagis®, is an HRSV-specific humanized monoclon l an ibody prepa ation
licensed for prophylactic use in infants at high risk of HRSV disease. It is administered monthly by
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intra-muscular injection, and the first dose should be given prior to the start of the HRSV season.
Although PZ does not necessarily prevent infants from becoming infected, it has been shown to help
prevent serious lung disease and reduce hospitalization rates [27]. Furthermore, PZ is sometimes used
off-label to treat hematopoietic stem cell recipients with HRSV infection. We tested the prophylactic
efficacy of PZ in immunocompromised ferrets, by intra-muscular injection´2, 0, and 2 DPI. In Figure 4,
viral loads detected by qPCR (green symbols) or virus isolation (purple symbols) in throat swabs
(square symbols) or nose swabs (triangle symbols) are plotted over time for IT inoculated animals in
group 2 (immunocompetent), group 4 (immunocompromised) and group 5 (immunocompromised
and prophylactically treated with PZ). VN antibody titers measured in serum are shown as grey
bars. PZ treatment induced significant but short-lasting VN antibody levels in the animals of group 5.
As a result, virus loads were initially reduced in these animals.
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Figure 4. RS l ( ) seru antibody responses in individual ferrets
at differen time points after IT infection with wild-type HRSV subgroup A. HRSV loads (left y-axis
and bottom -axis) de cted by qPCR and virus isolation are shown as purple symbols,
respectively. ir s loa s in throat and nose swabs are shown by square and triangle symbols,
respectively. VN serum antibody levels (right y-axis and top x-axis) are shown as reciprocal serum
dilution (log2) required for neutralization in 50% of RSV-infected cultures. In groups 2 and 4 VN
antibodies are exclusively produced by the animals in response to the HRSV infection, in group 5 they
can either be induced by PZ treatment (days -2, 0 and +2) or by de novo synthesis by the animals in
response to the infection.
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However, after 5 DPI virus loads started to increase, and a few days later these had
reached comparable levels as the animals of group 4. It is interesting to note that, although all
immunocompromised animals showed delayed virus clearance as compared to the immunocompetent
animals of group 2, we observed substantial individual variation. Both in group 4 and group 5, two
out of three animals became virus-negative between two and three weeks after infection, but one out
of three animals in each group was unable to clear the infection until after 21 DPI.
4. Discussion
In the present study we have demonstrated that ferrets are susceptible to infection with
a low-passage wild-type HRSV subgroup A strain. The virus replicated in the epithelial cells of both
the upper and lower respiratory tract, which resulted in virus shedding from the upper respiratory
tract detectable by quantitative virus culture and quantitative real-time RT-PCR. Furthermore, we have
shown that treatment of ferrets with a combination of immunosuppressive medication comparable
to the medication used in humans to prevent solid organ transplant rejection resulted in increased
and prolonged levels of HRSV replication. The ease of animal handling allowed for daily collection
of throat and nose swabs for measurement of viral loads, showing that ferrets may be a useful
animal model for the evaluation of novel vaccine strategies as well as for screening the efficacy
of novel antiviral compounds in preventing or treating HRSV infection in immunocompetent or
immunocompromised patients.
Prince and Porter have previously evaluated ferrets as an animal model of HRSV, by IN inoculation
of adult or infant ferrets with the laboratory-adapted Long strain of HRSV [22]. They observed
replication in respiratory epithelial cells in the URT of ferrets of all ages, but exclusively detected
replication in the LRT in infant ferrets. Interestingly, in these animals HRSV replicated in the alveolar
epithelial cells. In IT inoculated ferrets we clearly detected HRSV replication in bronchial epithelial
cells, which are also predominant target cells for HRSV in humans [28]. The major differences between
the two studies are the route of inoculation and the passage history of the virus. In our study, we
have no evidence to show whether IN inoculation of ferrets using an inoculum size of 0.3 mL (150 µL
per nostrum) resulted in efficient LRT infection. This will need to be addressed in future experiments
in which IN-inoculated animals will be euthanized at early time points. Although HRSV loads were
detected in throat swabs of both immunocompetent (Figure 1E) and immunocompromised (Figure 2E)
animals, this virus could have derived from either the URT or the LRT. Nevertheless, we expect that
the different outcomes of the two studies mainly result from the use of a laboratory-adapted versus
a wild-type HRSV strain. In other studies, the use of clinical isolates has also been associated with
different outcomes of infection both in vitro and in vivo [29–31].
Several animal models have been developed for HRSV, but none of these fully reproduce the
pathogenesis of severe HRSV disease observed in humans [32]. This is partly due to the complex
pathogenesis in humans, where primary infection can either result in subclinical virus replication,
mild disease, or severe disease requiring hospitalization. As we do not fully understand what drives
severe disease in humans, it is almost impossible to reproduce this disease in animals. One of
the major disadvantages of the ferret model as it is presented here is the apparent lack of clinical
signs. It may be possible to induce clinical signs by using a higher virus dose for primary infection,
but it is questionable whether that would really mimic human disease. Studies in which clinical
signs are of importance can probably better be performed using a natural host model such as the
bovine RSV model in calves or lambs [33,34]. A second drawback of the ferret model is the limited
availability of immunological reagents, which largely precludes in-depth immunological studies.
This is a major restriction, as HRSV bronchiolitis is associated with inflammation and is sometimes
considered an immune-mediated disease [35]. Therefore, murine models of HRSV will remain
indispensable to support our understanding of the mammalian immune response to HRSV. Finally,
our experiments with PZ show that these human immunoglobulins exhibit a short half-life in ferrets,
requiring an adjusted dosing schedule to address the efficacy in this animal model. These observations
are in accordance with previous studies that found limited effectiveness of human antibodies in the
Viruses 2016, 8, 168 11 of 14
infant ferret model, whereas maternal infection did provide protection against HRSV [36]. Still, the
ferret model of HRSV also has a number of strong advantages. First of all, ferrets appear to be highly
susceptible to infection with wild-type HRSV. In combination with the ease of handling the animals,
which allows for daily collection of throat and nose swabs, this allows sensitive detection of viral loads
at high resolution. Importantly, the viral load curves start at undetectable virus levels one or two days
after inoculation, demonstrating that the virus detected at later time points is not residual input virus,
but truly derives from de novo produced HRSV particles. In fact, the ferret studies resemble individual
case studies in humans. The fact that the ferrets are outbred non-SPF animals results in a significant
level of biological variation, but also brings the model closer to the real situation in humans, in which
similar variation is observed. Experiments in ferrets will often include fewer animals than those in
rodents, but this is compensated for by the fact that day-to-day collection of clinical specimens is much
easier. Finally, when compared to the prototypic highly susceptible animal model for HRSV, the cotton
rat, an important difference is the high level of HRSV replication in tracheal epithelial cells, which
appears to be absent in cotton rats [23]. Despite their high susceptibility, HRSV-infected cotton rats do
not transmit the virus to naive cage mates by direct transmission [37]. We will investigate whether
ferrets can be used for transmission studies, which would further strengthen their potential use in
preclinical testing of antiviral compounds.
A major strength of the ferret model is the potential to model infection of immunocompromised
animals using immunosuppressive medication regularly used in human transplant patients [8].
Respiratory virus infections are described as an important cause of severe respiratory tract disease in
immunocompromised patients [5,6,13,38]. The most prevalent respiratory viruses in this population
are rhinoviruses and coronaviruses [38], but severe respiratory tract infections are in most cases
caused by influenza viruses or paramyxoviruses, including HRSV [39]. With ongoing specialization,
academic hospitals have seen a shift in the profile of patients, resulting in an increased number
of immunocompromised patients with severe comorbidities. The majority of severe influenza
and paramyxovirus infections in adults involves patients with some form of immune dysfunction
related to preceding hematopoietic stem cell or solid organ transplantation, or to oncology treatment.
The immune suppression results in delayed viral clearance [8,9,40], leading to increased risk of
lower respiratory tract infection, potential for development of antiviral resistance, escape from
neutralizing antibodies, and risk of nosocomial spread [41,42]. Our findings obtained using the
immunocompromised ferrets resemble the increased viral loads and delayed viral clearance in humans,
as demonstrated by the day-to-day sampling of the immunocompromised ferrets. Animal models for
HRSV infection of the immunocompromised host have also been developed in mice and cotton rats,
resulting in more severe lung lesions or prolonged RSV replication, respectively [43,44]. However,
these models were based on the use of cyclophosphamide monotherapy, which is less commonly used
in humans than combination immune suppressive therapies. As ferrets provide an important animal
model for human influenza, we previously developed a protocol to induce immune suppression in
ferrets using medication routinely used in human transplant patients, and demonstrated prolonged
influenza virus replication [8]. Moreover, we also demonstrated that the use of antiviral compounds
could result in development of drug resistance. Based on the HRSV data presented in the current
manuscript, we believe that the HRSV model in ferrets can be used in parallel with the influenza model
for preclinical studies of antiviral efficacy and development of drug resistance.
5. Conclusions
In conclusion, the HRSV model in immunocompetent and immunocompromised ferrets can
complement existing animal models and contribute to the efficacy and safety of novel HRSV
intervention strategies.
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